Invex Therapeutics to acquire Rekover Therapeutics in all-stock deal
PERTH: Invex Therapeutics Limited (ASX: IXC) announced Monday it has entered a binding share purchase agreement to acquire 100% of Rekover Therapeutics Limited, a New Zealand biotechnology company repurposing nalfurafine for the treatment of demyelinating diseases, including chronic optic neuropathy…